Daiichi Sankyo exon-skips into ultra-orphan ring with DMD alliance
This article was originally published in Scrip
Executive Summary
Perhaps encouraged by strong global investor and clinician interest in companies developing new drugs for very rare orphan diseases, Daiichi Sankyo has unveiled plans for a new Japanese joint venture specializing in antisense oligonucleotides for the treatment of Duchenne muscular dystrophy (DMD).
You may also be interested in...
DMD Pipeline: After Sarepta’s First-Ever Approval, Are Combinations Next?
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: alarms sound over Omicron; Sanofi boosts vaccine pipeline via acquisition; J&J’s immunology plans; Chinese firms step onto world stage; and top execs share insights to shape India’s R&D push.
Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.